Jiangsu Hansoh Pharmaceutical Group Co., Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jiangsu Hansoh Pharmaceutical Group Co., Ltd
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.
Astellas’s Xtandi gets its latest approval in China, where Merck’s Keytruda is set for another win.
Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector.